Table 2. Summary relative estimates for glioma in women.
Exposure Categories | Heterogeneity | |||||
Risk factors | Highest(min to mix) vs. Lowest(minto mix) | Number of studies(Reference) | Pooled RR(95% CI) | PQ | I2 | PEgger’s |
OC | Ever vs. Never | 6 (20–24, 41) | 0.707(0.604–0.828) | 0.806 | 0.0% | 0.144 |
HRT | Ever vs. Never | 6 (20–24, 29) | 0.683(0.577–0.808) | 0.744 | 0.0% | 0.252 |
Menopausal status | Postmenopausal vs. Premenopausal | 5 (23, 24, 27, 29, 42) | 0.959(0.670–1.375) | 0.031 | 62.4% | 0.699 |
Parous status | Parous vs. nulliparous | 6 (21, 22, 24, 25–27) | 0.837(0.674–1.040) | 0.005 | 69.9% | 0.779 |
Age at menarche | Oldest (≥14) vs. Youngest(≤11 to ≤12) | 6 (21–24, 27, 41) | 1.401(1.052–1.865) | 0.038 | 57.6% | 0.076 |
Age at menopause | Oldest(≥50 to ≥53) vs. Youngest(≤40 to ≤50) | 5 (21–24, 27) | 0.972(0.782–1.209) | 0.714 | 0.0% | 0.093 |
Age at first birth | Oldest(≥30 to ≥35) vs. Youngest(≤20 to ≤25) | 6 (21, 22, 24–27) | 1.153(0.879–1.513) | 0.105 | 45.1% | 0.146 |